Sleuth Studio
Customer Stories

How Juvena’s CSO keeps up with a first-in-class pipeline

Sleuth Studio lets one person do deep analysis and triage across a first-in-class pipeline. Juvena Therapeutics’ discovery work turns up targets across hundreds of indications, and co-founder and CSO Jeremy O’Connell researches each new target in Studio: the biology behind it, who else is drugging it, and how fast a trial could show it works.

Juvena Therapeutics

How Juvena’s CSO keeps up with a first-in-class pipeline

Download the full case study

Partner

Juvena Therapeutics is a platform biotech that develops medicines from proteins secreted by stem cells. Co-founder and CSO Jeremy O’Connell directs R&D strategy across muscle, bone and cartilage, and inflammation.

Challenge

Juvena finds targets across diverse fields and can’t staff specialists for every protein. Jeremy needs to understand each one well enough to decide what to pursue.

Approach

Jeremy brings the criteria, and Studio does the research. For every target, it layers competitive, clinical, and biological evidence from trials, patents, papers, genetics, and deals, and explains how each one measures up.

Outcome

Jeremy does a research team’s work for Juvena’s whole pipeline in Studio, from portfolio triage to program biology. In one run, he triaged 21 unfamiliar targets in about an hour and sent the best into go/no-go review.

“We do a lot of first-in-class work, so for every new target we need to know an incredible amount of information quickly. Sleuth kills everything that’s not obviously good, so we can spend our time on the few that might be a gold mine. In minutes, it’s another FTE worth of information coming back to me.”

Jeremy O’Connell, PhD

Jeremy O’Connell, PhD

Co-founder and Chief Scientific Officer, Juvena Therapeutics

Every line of research, from portfolio to program, run by one person

Seven lines of research Jeremy runs in Studio, from portfolio-wide triage to the biology behind a lead program, with an example question and a project count for each.

From PatSnap to Studio

Jeremy moved his landscapes and target reviews from PatSnap to Studio. Studio puts patent-only programs in the same landscape as everything else, with the patents behind each one and the deals around them.

Head to head with Gemini

When Jeremy has put the same question to Gemini and to Studio, Studio has come out ahead. Gemini answers from the open web; Studio answers from trial registries, patents, and papers, and shows him which ones.

A deep triage on 21 unfamiliar targets, in about an hour

Jeremy’s discovery work turned up 21 targets no one at Juvena had studied. He set up a Studio project for each, and in about an hour Studio built every one a dataset of competitive, clinical, and biological evidence from trial registries, patents, papers, genetic databases, and deals, judged against his criteria.

21 targets split into 12 with room to pursue, 3 too crowded, and 6 already in the clinic or failed.

The same five questions, answered for every target

One target’s answers to five questions on genetics, biology, competition, clinical path, and partnering.
Target B, one of the 21, as Studio laid it out. Details are illustrative.

Any criteria Juvena names, evaluated against the evidence

Then Jeremy went deeper on the 12 that made it through, asking Studio sharper questions of his own, like whether the biology holds up in human muscle or which papers to trust when they disagree. For each answer, Studio searched a knowledge base of 1M+ trials, 150K+ drugs, 300K+ patents, and the published literature, and showed the reasoning behind every score.

A Studio workspace scoring 12 musculoskeletal targets, with one target opened to show why two null mouse studies got less weight.
Rebuilt from Jeremy’s workspace. Targets, scores, and sources are illustrative.

The top three went into Juvena’s go/no-go review.

Download
Use case

Size up your next target on your own criteria

Bring your own asset, target, or indication, and Sleuth builds the analysis for you.

More from Sleuth